Back to top

Vertex Pharmaceuticals (VRTX) Receives a Hold from Morgan Stanley

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $4...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Vertex Pharmaceuticals Incorporated (VRTX)